Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.35 |
| ▸ | BCL9 | O00512 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556964 | 0.82 | KMT2A (0.49) | KMT2AEPHX2HTR2AMAPTHTT | |
| SCHEMBL31476468 | 0.81 | KMT2A (0.42) | KMT2AEPHX2HTR2AMAPTHTT | |
| SCHEMBL14685603 | 0.81 | KMT2A (0.56) | KMT2AEPHX2MAPTHTTRAB9A | |
| SCHEMBL30242885 | 0.81 | KMT2A (0.56) | KMT2AEPHX2MAPTHTTRAB9A | |
| SCHEMBL3131957 | 0.80 | SMN1; SMN2 (0.40) | KMT2AHTR2ASMN1; SMN2SSTR1SSTR3 | |
| SCHEMBL3829326 | 0.79 | MGLL (0.54) | KMT2AEPHX2MAPTHTTRAB9A | |
| SCHEMBL3131952 | 0.79 | CASP3 (0.43) | KMT2AEPHX2HTR2AMAPTHTT | |
| SCHEMBL31548905 | 0.79 | KMT2A (0.46) | KMT2AEPHX2HTR2AMAPTHTT | |
| SCHEMBL31520512 | 0.79 | CYP1A2 (0.43) | KMT2AEPHX2HTR2AMAPTHTT | |
| SCHEMBL31520518 | 0.78 | HTR2A (0.43) | KMT2AEPHX2HTR2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704924-B2 | Library of compounds comprising pyrrolobenzodiazepine moieties | SPIROGEN LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-20040092736-A1 | Collections of compounds | SPIROGEN LIMITED | 2004-05-13 | — | — | US | disclosed |
| US-6608192-B1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092736-A1 | Collections of compounds | CBR3, CYCS, CBR1 | KMT2A 2225/4885EPHX2 385/4885HTR2A 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.